"id","uuid:ID","instanceType","versionIdentifier","rationale"
"StudyVersion_1","32a25661-c3d5-47ef-a052-a82d8f09eb09","StudyVersion","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
